SOHO 2022 | The use of daratumumab in transplant-eligible & transplant-ineligible patients with multiple myeloma
Claudio Cerchione
• 28 Sep 2022
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, comments on the addition of daratumumab in the treatment regimen of patients with multiple myeloma who are transplant-eligible and transplant-ineligible in Italy, highlighting the advantages of this drug. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
